15
3.2.2. White-Coat Hypertension and Masked Hypertension,
and White-Coat Effect and Masked Uncontrolled Hypertension
COR LOE
Recommendations
2a B-NR
1. In adults with untreated office SBP ≥130 mm Hg or DBP
≥80 mm Hg, and without office SBP ≥160 mm Hg or
DBP ≥100 mm Hg, it is reasonable to exclude white-coat
hypertension using out-of-office BP monitoring before a
diagnosis of hypertension is made.
2a B-NR
2. In adults with white-coat hypertension or masked
hypertension, out-of-office BP monitoring is reasonable to
exclude transition to a diagnosis of sustained hypertension.
2a C-LD
3. In adults with apparent treatment-resistant hypertension on
office BP, it is reasonable to exclude white-coat effect, a form
of pseudoresistance, using out-of-office BP monitoring.
2a B-NR
4. In adults who are taking antihypertensive medication and
have elevated office BP (office SBP ≥130 mm Hg or DBP
≥80 mm Hg ) but do not have resistant hypertension or office
SBP ≥160 mm Hg or DBP ≥100 mm Hg, it is reasonable to
exclude white-coat effect using out-of-office BP monitoring.
2b B-NR
5. In adults with untreated office SBP <130 mm Hg and
DBP <80 mm Hg, it may be reasonable to exclude masked
hypertension using out-of-office BP monitoring.
2b B-NR
6. In adults who are taking antihypertensive medication and
have office SBP <130 mm Hg and DBP <80 mm Hg, it may
be reasonable to exclude masked uncontrolled hypertension
using out-of-office BP monitoring.
